The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)

被引：16
|
作者：
Maciejewska-Markiewicz, Dominika [1 ]
Stachowska, Ewa [1 ]
Hawrylkowicz, Viktoria [1 ]
Stachowska, Laura [1 ]
Prowans, Piotr [2 ]
机构：
[1] Pomeranian Med Univ, Dept Human Nutr & Metabol, PL-70204 Szczecin, Poland
[2] Pomeranian Med Univ, Clin Plast Endocrine & Gen Surg, PL-72009 Police, Poland
来源：
BIOMOLECULES | 2021年 / 11卷 / 07期
关键词：
NAFLD; n-3; PUFA; resolvins; protectins; marensins; LEUKOTRIENE A(4) HYDROLASE; ANTIINFLAMMATORY ACTIONS; RESOLUTION; MEDIATORS; ACID; D1; INFLAMMATION; STEATOSIS; OMEGA-3-FATTY-ACIDS; ACCUMULATION;
D O I：
10.3390/biom11070937
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Increased triacylglycerols' (TAG) synthesis, insulin resistance, and prolonged liver lipid storage might lead to the development of non-alcoholic fatty liver disease (NAFLD). Global prevalence of NAFLD has been estimated to be around 25%, with gradual elevation of this ratio along with the increased content of adipose tissue in a body. The initial stages of NAFLD may be reversible, but the exposition to pathological factors should be limited. As dietary factors greatly influence various disease development, scientists try to find dietary components, helping to alleviate the steatosis. These components include n-3 polyunsaturated (PUFA) fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acids (DHA). This review focused on the role of resolvins, protectins and merensins in NAFLD.
引用
收藏
页数：9
相关论文
共 50 条
  • [21] Non-alcoholic fatty liver disease (NAFLD) - epidemic of the XXI century
    Maciejewska, Dominika
    Stachowska, Ewa
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2018, 72 : 659 - 670
  • [22] Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation
    Lyall, Marcus J.
    Thomson, John P.
    Cartier, Jessy
    Ottaviano, Raffaele
    Kendall, Timothy J.
    Meehan, Richard R.
    Drake, Amanda J.
    EPIGENETICS, 2020, 15 (1-2) : 61 - 71
  • [23] Beverages and Non-alcoholic fatty liver disease (NAFLD): Think before you drink
    Chhimwal, Jyoti
    Patial, Vikram
    Padwad, Yogendra
    CLINICAL NUTRITION, 2021, 40 (05) : 2508 - 2519
  • [24] A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
    Tilg, Herbert
    Effenberger, Maria
    Adolph, Timon E.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 103 - 106
  • [25] The Role of Non-Alcoholic Fatty Liver Disease in Infections
    Krznaric, Juraj
    Vince, Adriana
    LIFE-BASEL, 2022, 12 (12):
  • [26] Role of mitochondria in non-alcoholic fatty liver disease
    Pessayre, Dominique
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 : S20 - S27
  • [27] Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
    Burra, Patrizia
    Bizzaro, Debora
    Gonta, Anna
    Shalaby, Sarah
    Gambato, Martina
    Morelli, Maria Cristina
    Trapani, Silvia
    Floreani, Annarosa
    Marra, Fabio
    Brunetto, Maurizia Rossana
    Taliani, Gloria
    Villa, Erica
    LIVER INTERNATIONAL, 2021, 41 (08) : 1713 - 1733
  • [28] Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Ahsan, Farah
    Oliveri, Federico
    Goud, Harshit K.
    Mehkari, Zainab
    Mohammed, Lubna
    Javed, Moiz
    Althwanay, Aldanah
    Rutkofsky, Ian H.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
  • [29] The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease
    Francque, Sven M.
    EUROPEAN CARDIOLOGY REVIEW, 2014, 9 (01) : 10 - 15
  • [30] Beyond the liver in patients with non-alcoholic fatty liver disease (NAFLD)-cause for concern?
    Armstrong, Matthew J.
    Haydon, Geoffrey
    Syn, Wing-Kin
    HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (02) : 138 - 142
12345